Seller record · Telehealth service

Bioverse

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 1 of 8 criteria. S3, pharmacy identification: The answers page says the partner pharmacies are listed behind a link that leads nowhere, and no pharmacy is named in the terms, the privacy policy, the product pages or the certificates of analysis, which print only a Houston facility address.

At a glance

BioverseTelehealth service

7/8criteria passed

Price: Semaglutide from $129 a month, listed at $289
Sells: compounded semaglutide, compounded tirzepatide, Ozempic, and 9 more
FDA letters: 1 on file

Visit Bioverse See all eight dispositions

Telehealth service. Passes 7 of 8 criteria. Recorded against Standard v1.1.

A longevity telehealth service selling compounded semaglutide and tirzepatide, brand Ozempic, Wegovy and Mounjaro, and NAD+ and glutathione injections, with a certificate of analysis published for each compounded GLP-1. It names no filling pharmacy, and an FDA warning letter from September 2025 names the company.

Operating entity Bioverse, Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Bioverse's website; Bioverse's terms of use page; Bioverse's consent to telehealth page
S2	Prescription gating	PASS	Bioverse's registration page on its app site; Bioverse's NAD+ injection product page
S3	Pharmacy identification	FAIL	Bioverse's FAQ; Bioverse's terms of use page; Bioverse's product COAs page
S4	Compounding disclosure	PASS	Bioverse's semaglutide product page; Bioverse's tirzepatide product page
S5	Analytical documentation	PASS	Bioverse's product COAs page
S6	Business address	PASS	Bioverse's terms of use page
S7	Price disclosure	PASS	Bioverse's semaglutide product page; Bioverse's tirzepatide product page; Bioverse's NAD+ injection product page; Bioverse's glutathione injection product page; Bioverse's Ozempic product page; Bioverse's Wegovy product page
S8	Enforcement status	PASS	FDA's website; FDA warning letter 716508

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA provider licensed in the buyer's state reviews the health information and prescribes only if appropriate, and the terms name Outlast Health, P.A. and affiliated medical groups as the providers.Source: Bioverse's website; Bioverse's terms of use page; Bioverse's consent to telehealth page.

S2PASSThe eligibility button opens a sign-up screen headed as a check of whether the buyer qualifies for medical weight loss, with no payment screen before it, and the product pages state that the buyer is charged only if a provider prescribes.Source: Bioverse's registration page on its app site; Bioverse's NAD+ injection product page.

S3FAILThe answers page says the partner pharmacies are listed behind a link that leads nowhere, and no pharmacy is named in the terms, the privacy policy, the product pages or the certificates of analysis, which print only a Houston facility address.Source: Bioverse's FAQ; Bioverse's terms of use page; Bioverse's product COAs page.

S4PASSThe semaglutide and tirzepatide pages state that the compounded products are not FDA-approved and are not approved or evaluated for safety, effectiveness or quality by the FDA.Source: Bioverse's semaglutide product page; Bioverse's tirzepatide product page.

S5PASSThe certificates page links a certificate of analysis for compounded semaglutide, lot 15778052, and for compounded tirzepatide, lot 15861255, each reporting potency, sterility and endotoxin results from a third-party laboratory.Source: Bioverse's product COAs page.

S6PASSBioverse, Inc. at 875 Washington Street, New York, NY 10014, printed in the terms, which print the ZIP as 10019 in their contact section.Source: Bioverse's terms of use page.

S7PASSCompounded semaglutide from $129 a month against a struck-through $289, compounded tirzepatide from $399 against $449, the NAD+ injection from $259 against $339 and the glutathione injection from $149 against $165. Brand Ozempic from $1,699 a month against $1,799 and Wegovy from $1,899 against $1,999. The eligibility screen announces a limited time sale.Source: Bioverse's semaglutide product page; Bioverse's tirzepatide product page; Bioverse's NAD+ injection product page; Bioverse's glutathione injection product page; Bioverse's Ozempic product page; Bioverse's Wegovy product page.

S8PASSFDA warning letter 716508, September 2025, names Bioverse, Inc. dba Bioverse at 875 Washington Street, New York, the address the site prints, and alleges that claims of the same active ingredient as Ozempic, Wegovy, Mounjaro and Zepbound are false or misleading for its compounded semaglutide and tirzepatide. No FDA action has halted the business, and the company continues to operate.Source: FDA's website; FDA warning letter 716508.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, Ozempic, Wegovy, Mounjaro, NAD+ injection, NAD+ face cream, glutathione injection, B12 injection, metformin, tadalafil and sildenafil, finasteride and minoxidil spray.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide Who sells NAD+Who sells glutathione

Enforcement documents on file: 1 warning letter

FDA warning letter 716508, issued September 2025, to Bioverse, Inc. dba BioverseClaims that the compounded semaglutide and tirzepatide carry the same active ingredient as Ozempic, Wegovy, Mounjaro and Zepbound imply the products are the same as FDA-approved drugs, which the letter calls false or misleading.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit Bioverse

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.